Stay updated on ARGX-113 in Myasthenia Gravis: Safety Trial
Sign up to get notified when there's something new on the ARGX-113 in Myasthenia Gravis: Safety Trial page.

Latest updates to the ARGX-113 in Myasthenia Gravis: Safety Trial page
- Check3 days agoChange DetectedThe web page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference2%
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe page has removed a citation regarding the safety, efficacy, and tolerability of efgartigimod in patients with generalized myasthenia gravis, which is a significant study in the field.SummaryDifference0.4%
- Check31 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check45 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed trial descriptions and eligibility criteria for the ARGX-113 study, while a new revision number has been added.SummaryDifference14%
- Check53 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check60 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
Stay in the know with updates to ARGX-113 in Myasthenia Gravis: Safety Trial
Enter your email address, and we'll notify you when there's something new on the ARGX-113 in Myasthenia Gravis: Safety Trial page.